If the AD p2a/3 trial is as successful as many of the posters anticipated, the millions spent in PD ph3 is just a drop in the 20 billion market cap gain bucket. On the other hand, if the AD p2a/3 trial results are not as convincing (as the SP indicated), the PD p3 will be the only trial with outcome in the 2024 pipeline. Investors invest in drug pipeline not cash in hand.
Compared to AD, PD is such a low hanging fruit for A2-73: Only one primary endpoint (UPRS score), half of the trial duration, much younger patients (one dose at 50mg). Together,. PD trial has much higher chance to succeed. It’s a no brainer to start as soon as an SPA is obtained from FDA.
The positive PD p3 trial might also serve a purpose as the 2nd AD p3. An added bonus.